Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology

Roivant Sciences Ltd.
Pfizer Inc.
BioNTech

Roivant Sciences Ltd.

ROIV

0.00

Pfizer Inc.

PFE

0.00

BioNTech

BNTX

0.00
  • Roivant unit Genevant joined Arbutus in filing patent infringement suits against Pfizer, BioNTech over lipid nanoparticle technology used in mRNA COVID-19 vaccines.
  • Actions target patents including Canadian Patent No. 2,721,333, EP 4 241 767, EP 4 495 237, seeking damages and injunctions.
  • Arbutus received USD 178 million from Moderna under a March 2026 settlement over LNP patents.
  • Arbutus plans up to about USD 230 million in share repurchases starting in Q3 2026, contingent on a Genevant-related dividend.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.